Table 3:
Multivariate adjusted ORs for the risk of MACE in relation to the current use of bezafibrate, fenofibrate and pemafibrate compared with non-use.
| n (%) | OR (95% CI) | |||
|---|---|---|---|---|
| Cases | Controls | Adjusted | P-value | |
| No current fibrate use | 15 605 (98.6) | 31 174 (98.5) | 1 (reference) | |
| Current use of bezafibrate | 92 (0.6) | 195 (0.6) | 0.91 (0.692–1.201) | .509 |
| Current use of fenofibrate | 61 (0.4) | 147 (0.5) | 0.77 (0.554–1.082) | .134 |
| Current use of pemafibrate | 72 (0.5) | 144 (0.5) | 0.73 (0.528–0.997) | <.05 |
Covariates list: age, sex, eGFR category, diabetes, atrial fibrillation/flutter, ischemic heart disease, cerebrovascular disease, peripheral vascular disease, chronic pulmonary disease, angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers, β-blockers, calcium channel blockers, statins, diuretics, anticoagulants, antiplatelet agents, sodium-glucose cotransporter 2 inhibitor, glucagon-like peptide-1 receptor agonist, glucocorticoid inhalant, steroids, NSAIDs, opioids, antidepressant and calendar year of cohort entry.